Opinion of the Transparency Council – paclitaxelum
At its meeting on 30 June 2025, the Transparency Council adopted opinion No. 112/2025 on the appropriateness of transferring the active substance paclitaxelum albuminatum from drug program B.85. “Treatment of patients with pancreatic adenocarcinoma (ICD-10: C25.0, C25.1, C25.2, C25.3, C25.5, C25.6, C25.7, C25.8, C25.9)” to the list of reimbursed drugs in chemotherapy